Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TITANIA phase 3 trial of tozorakimab in symptomatic COPD with exacerbation history
MOH_2022-07-03_011885Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Tozorakimab every 4 weeks, Tozorakimab every 8 weeks with alternating matched placebo and Matched placebo every 4 weeks (3 arms). Started Jun 2022; status: completed.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on MOH_2022-07-03_011885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-07-03_011885.